Twenty-nine dogs were treated with linac-based stereotactic radiation therapy (SRT) for nonlymphomatous nasal tumours. Only dogs with a follow-up time >365 days were included in this retrospective analysis. No dogs had evidence of distant metastasis at diagnosis. Treatment was planned and a total of 30 Gy in 3 daily 10 Gy fractions was delivered using intensity-modula- 
| INTRODUCTION
Nasal tumours are locally invasive and result in clinical signs such as epistaxis, sneezing and nasal discharge. Fractionated, definitive-intent external beam radiation therapy (RT) is currently considered the standard of care. Numerous published reports of dogs being treated in this manner exist, consisting of 10-19 fractions of 2.5-4.2 Gy for a total dose of 36-57 Gy. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] The majority of dogs treated experience a clinical benefit, and reported survival times (STs) for such protocols range from 7
to 23 months, with 1-and 2-year survival rates of 37%-60% and 17%-48%, respectively. Acute side effects associated with these protocols are typically moderate to severe and can include mucositis, desquamation, keratitis and conjunctivitis. The acute side effect profile may be improved with the use of modern radiotherapy planning and delivery techniques such as intensity-modulated RT (IMRT). 11, 12 The treatment schedule, cost and acute side effects associated with fractionated radiation therapy protocols may preclude some pet owners from choosing this treatment.
Stereotactic radiation therapy (SRT) is a form of severely hypofractionated, dose-intense RT that involves precise delivery of large fractional doses of radiation to a well-defined target with a rapid falloff of dose, allowing nearby critical structures (organs at risk, OAR) to be spared from many of the acute side effects associated with traditional fractionated RT. This form of RT is becoming increasingly available at veterinary facilities, and 2 publications to date have documented use of SRT for the treatment of nasal tumours in dogs. 13, 14 The purpose of this study was to describe tumour-associated outcomes in dogs with non-lymphomatous nasal tumours and the side effects associated with an SRT protocol (10 Gy × 3, daily) delivered by linear accelerator based, image guided, IMRT. Our hypothesis was that this protocol would provide a clinical benefit for the majority of treated dogs and would result in minimal acute side effects.
| MATERIALS AND METHODS
Cases in which owners chose SRT between August 2013 to February 2016 were included and were all treated with a standardized SRT protocol. A retrospective analysis of records of dogs treated with this protocol at our institution was performed. Dogs were included if they had biopsy-confirmed non-lymphomatous nasal tumours and a minimum follow-up time of 365 days post-SRT. Dogs treated with chemotherapy were excluded. Required staging tests prior to SRT included bloodwork, radiographs and/or CT scans to evaluate for thoracic metastasis, and CT scans of the nasal cavity for radiation treatment planning. Baseline ophthalmology consultations (to assess for the presence of pre-existing intraocular abnormalities) were recommended in all cases. Bilateral mandibular lymph node aspirates to assess dogs for lymph node metastasis were recommended in all cases. Abdominal cavity imaging with ultrasound or CT scan was recommended in all cases to examine dogs for co-morbidities. Followup examinations were recommended at 21 and 42 days and 90, 180, 270 and 365 days post-SRT, and CT scans were recommended at 90-120 day intervals. Additional follow-up information was also obtained through phone and email contact with owners and referring specialists and/or primary care veterinarians at 90-day intervals.
Dogs were anesthetized for the delivery of radiation. Anaesthetic protocols varied but in most cases consisted of an opioid premedication followed by a propofol (Diprovan, AstraZeneca, London, UK) induction and maintenance with isoflurane gas (Aerrane, Baxter, Haryana, India).
| Tumour staging based on RT planning CT scans
The modified Adams' staging system was used to categorize tumours based on RT planning CT scans. 15 In addition, dogs with stage T4 tumours were further subcategorized as having intracranial extension of the tumour or not.
| Radiation treatment planning
The gross tumour volume (GTV) was contoured using pre-and postcontrast 1-2 mm slice thickness CT image sets, and included contrast-enhancing mass and any fluid as well as a thin (~1 mm) bony margin. The clinical target volume (CTV) was created on transverse CT images as a 5-10 mm expansion (dependent on patient size) into the contralateral nasal cavity. A 10 mm rostral and caudal margin were added to the CTV within the nasal cavity which did not include the nasal planum in any case ( Figure 1 ). This CTV was created to attempt to treat microscopic disease extensions that could have been present along the nasal turbinates. If subcutaneous extension was present, the extension was contoured as GTV, but a separate structure, "GTV minus skin," was used for GTV optimization purposes (ie, the skin was cropped from the GTV). This was done to try to decrease the likelihood of hot spots in the skin (OAR dose constraints were applied to the skin as described below) and the possible increased risk of nasocutaneous fistulas if hot spots were present.
The CTV and GTV were equivalent within the cranial vault. No additional planning target volume (PTV) expansion was used (CTV = PTV).
In all cases, the PTV contained air within sinonasal cavities.
OAR that were contoured included both eyes and lenses, both ears (including cochlea, middle ear and horizontal canal), skin (a 2 mm wall was extracted internally from the body contour to create the skin contour), palatal mucosa (2 mm thickness in all cases), brain, spinal cord and optic chiasm. To quantify (and minimize, through IMRT optimizations) normal brain dose, a "Brain Less PTV + 2 mm" structure was created (a 2 mm fall off surrounding the PTV was allowed into the brain due to dosimetric limitations/penumbra). Another spare structure, "Brain Spare," was created using an additional 3-4 mm margin inside of the "Brain Less PTV + 2 mm." Additional spare structures were created as needed to improve OAR dose constraints and to improve dose homogeneity/reduce hot spots in the plan. Thirty Gray (Gy) was prescribed to 99% of the GTV and ≥95% of the PTV. Isotropic margins of 2-4 mm were created within the GTV (in all cases where the GTV was large enough for both the 2 and 4 mm internal boost structures to be created) to facilitate a simultaneous integrated boost (SIB) of 36-39 Gy (with no point doses higher optimizations and use of both coplanar and non-coplanar beams when necessary. In addition to these constraints, the integral dose to the brain (goal was to achieve less than 15% of the brain > 10 Gy), eyes (goal was to minimize volume >10 Gy) and lenses (goal was to minimize volume > 6 Gy) was minimized in a similar fashion. Conformity index (CI) and gradient index (GI) were used to assess plans retrospectively and were not used in the process of plan approval. The CI is a concept to quantitatively assess the degree of conformity of dose distribution and can be used in conjunction with dose volume histogram and dose distribution data to judge the overall quality of radiation plans. 19 A value of 1 means that the reference The GI is an objective tool to assess how rapidly the dose falls off outside of the target. 19 GI was defined as volume of body getting 50% of prescription (15 Gy) divided by volume of body getting 100% of prescription (30 Gy). A lower GI indicates a steeper dose gradient.
In a retrospective study of gamma knife plans, a GI of <3.0 was an ideal value. 19 Since CI and GI were retrospectively evaluated, there was no defined cutoff below which plans were deemed unacceptable.
| Assessment of adverse effects
The Veterinary Radiation Therapy Oncology Group toxicity scoring system was used to prospectively document and describe toxicities associated with SRT. 20 Acute toxicities were defined as those that occurred less than 90 days after SRT and late toxicities were defined as those that occurred greater than 90 days after SRT. 
| Statistical analysis

Impact of these categorical and continuous variables on ST and PFS
were also evaluated using a Cox-proportional hazards model (SPSS Statistics 24), with all factors found to have a P-value <.10 on univariate analysis, further assessed in a multivariate analysis, with significance defined as P < .05. Correlations between GI and both body weight (BW) and planning target volume (PTV) were assessed; correlations with P < .1 in a univariate model were moved into a multiple regressions analysis with significance defined as P < .05. 
| RESULTS
Twenty
| Clinical benefit and side effects
Subjectively, clinical signs improved in all cases as noted by owners and clinicians, typically within 7-14 days post-SRT. Acute toxicity in the 14-28 days following SRT was limited to grade I alopecia and mucositis (N =2); however, not all patients returned to our institution for the initial recheck after SRT, so it is possible that acute toxicities were under- 
| Analysis of ST
At the completion of the study, 11 of 29 dogs were alive. The median ST was 586 days (95% CI: 448-724 days; Figure 6 ) with a median follow-up time of 545 days (range, 419-1086) in censored subjects;
69% were alive at 1 year and 22% were alive at 2 years post-SRT. progression-free at 1 year and 39% were progression-free at 2 years.
| Analysis of progression-free survival (PFS)
The median follow-up time for censored cases was 487 days (range:
36-1009). 
| Reirradiation
| Effect of tumour stage on outcome
As there were not enough dogs with stage T3 disease to evaluate this category independently, and because the strongest factor predictive of outcome for nasal tumours with other irradiation protocols is cribriform lysis, 15 dogs were grouped into stage T1-T3 (N = 16) vs stage T4 (N = 13)
disease. There was no statistical significance between groups for either ST (P = .737) or PFS (P = .147). Similarly, the presence of intracranial invasion by the tumour did not impact either ST (P = .600) or PFS (P = .542).
| Effect of tumour type on outcome
Tumours were categorized as carcinomas (N = 21) or sarcomas (N = 8). There was no statistical significance between groups for either ST (P = .133) or PFS (P = .490).
| Dosimetric parameters, CI, GI
There was no statistical significance found in any dosimetric parameter, CI or GI for either ST or PFS (see Table 1 ). Use of the CI and GI to assess RT plans is relatively novel in veterinary radiation oncology but should be reported in future studies. The CI is an objective measure of how well the distribution of radiation conforms to the size and shape of a target. 19 fistulas. 1, 13 In the dogs of this study, the skin was defined as the inner 2 mm of the body contour and specific dose constraints were applied to this OAR. This definition of skin was suggested by the authors of a study that explored the differences between actual dose delivered
(measured with Gafchromic film) as compared with the dose calculated by the AAA algorithm (using 1, 2 and 5 mm calculation voxel dimensions with 2 mm thick CT slices) in the Eclipse treatment planning system. 22 Dose at the surface and in the buildup region was measured in canine cadaver limbs treated with multiple coplanar and tangential beams (SRT plans). Eclipse underestimated the surface dose by 9%-11% as compared with the average measured dose, and dose comparisons in the buildup region determined that the dose is most reliable starting at 2.5 mm from the surface. Based on these results, the authors recommended defining the skin organ as the outermost 2-3 mm of the body and evaluating the dose at the deepest depth of that tissue in order to assess the most accurate dose to that OAR. Owing to this inherent variability in planned vs delivered dose, it is possible that the dose to the skin as visualized on the treatment planning system was underestimated in some dogs of this study, and the higher delivered doses predisposed certain patients to fistula formation.
In other published studies of dogs treated with SRT, osteonecrosis and seizures were the most commonly reported late effects. 13, 14 Notably different from this study, however, Kubicek et al used single fraction cone-based SRT, which likely increased late toxicity. 14 No dogs in the present study were known to have osteonecrosis. Two dogs in this study developed seizures within 60 days after SRT; 1 had presumed CNS metastasis of the tumour (based on MRI imaging) and the other had lymphoplasmacytic meningitis (confirmed at necropsy).
Late toxicities after RT are poorly documented in the clinical veterinary literature due to lack of consistent follow-up examinations after treatment and short STs in many patients. In this study, a minimum of 365 days of follow-up was acquired for each case, and since all but one of the late toxicities described here occurred~1 year or longer after SRT, it is possible that with continued regular follow-up exams (including ophthalmic exams) and/or necropsies, additional late toxicities could be documented.
ST and PFS in dogs of this study were longer than in some previously published studies of nasal tumours. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] This modest improvement could be related to differences in the contouring methods used here including reviewing both pre-and post-contrast bone and soft tissue windows to best ensure GTV definition, including a 1 mm rim of bony margin adjacent to the GTV and CTV, and/or use of simultaneous integrated boost structures that allow dose constraints to the OAR to be met while delivering a higher dose to the GTV. Although continued dose escalation may be a consideration for future studies to determine if higher doses to the target can consistently result in improved tumour control and survival, this approach should be met with caution since further dose escalation would undoubtedly increase the risk of late effects to OAR, and careful prospective evaluation would be required.
A PTV margin was not used as part of this protocol. This was justified by positioning that was based on image matching to immovable bony landmarks using a CBCT, with errors corrected using a robotic couchtop with 6 degrees of freedom, and routine QA by a medical physicist, which has verified the ability of the machine to deliver plans with submillimeter accuracy; furthermore, the described anaesthetic protocols and positioning devices minimized intrafraction motion. It is possible that due to a lack of a PTV, in some cases, parts of the GTV and/or CTV may not have received 95% of the dose (it could have been less or more). These potential variations between planned and delivered dose could have affected both outcome and toxicity.
Limitations of this study included lack of a single pathologist reviewing the histopathology in each case and lack of complete staging (lymph node aspirates) in each case. Although there was no difference in outcome in dogs with sarcomas vs carcinomas in this study, it is possible that a larger study of dogs with nasal carcinomas only could have allowed further elucidation in regards to possible differences in outcome between different histologic variants of carcinomas, as has been reported in other studies. 15 In addition, as with many studies of nasal cancers in veterinary patients, local tumour recurrence for some dogs in this study was based on a presumption due to the progression or recurrence of clinical signs rather than objective data including CT scans and biopsies. This presumption could lead to an overestimation of local tumour progression and could falsely decrease the PFS. Alternatively, without objective measurements, local tumour progression could be underestimated if dogs did not display clinical signs as tumours progressed. Finally, although most dogs did return to our institution at some point for follow up, not all pets were routinely examined as recommended for evidence of toxicities.
| CONCLUSION
In this study, a linac-based SRT protocol delivering 30 Gy in 3 fractions over 3-5 days was used to treat non-lymphomatous nasal tumours in 29 dogs with limited adverse events, and clinical improvement in all cases. In addition, objective clinical responses were confirmed via CT scans 90-120 days post-SRT in all cases evaluated with repeat CT scans. The median PFS of 354 days and median ST of 586 days are similar or superior to previously published studies of dogs treated with various RT protocols. Continued accrual and follow up will be necessary to confirm a low incidence of late radiation toxicity, and further elucidate effects of stage and tumour type on outcome, thus more fully characterizing clinical efficacy.
